Abortion pills: under whose control?
Author:
Open Access
- 27 March 2012
- journal article
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 38 (2) , 117-122
Abstract
Early medical abortion has a key role to play in reducing unsafe abortion around the world, particularly in resource-poor settings where inadequate surgical services for abortion entail a high risk of infection and reproductive tract injury.7 An important signal went out in July 2005, when the regimen of mifepristone and misoprostol was included on the World Health Organization's WHO Model List of Essential Medicines.7 The Concept Foundation (http://www.conceptfoundation.org/medical-abortion.php) has registered Medabon® in Cambodia, India and Nepal; this is the first product to package mifepristone and misoprostol together. The Medabon introduction programme aims to launch this dedicated combination pack in 26 low- and middle-income countries.Keywords
This publication has 31 references indexed in Scilit:
- Introduction and provision of medical abortion: a tale of two countries in which technology is necessary but not sufficientContraception, 2011
- The role of Advanced Nurse Practitioners in the availability of abortion servicesBest Practice & Research Clinical Obstetrics & Gynaecology, 2010
- Pharmacy worker practices related to use of misoprostol for abortion in one Mexican stateContraception, 2009
- Medical Abortion in Early Pregnancy2009
- Review of medical abortion using mifepristone in combination with a prostaglandin analogueContraception, 2006
- Access to safe abortion within the limits of the lawBest Practice & Research Clinical Obstetrics & Gynaecology, 2006
- Misoprostol and illegal abortion in Rio de Janeiro, BrazilThe Lancet, 1993
- Cytotec in Brazil: ‘At least it doesn't kill’Reproductive Health Matters, 1993
- Progesterone receptor blockageContraception, 1985
- The Antiprogestin Steroid RU 486 and Human Fertility Control1985